NEW ALBANY, IN, RxLightning has closed a $17.5 million Series A investment.
RxLightning, creator of the industry's first comprehensive platform for streamlining specialty medication access and affordability, announced that it has closed a $17.5 million Series A investment to support the company's growth and further remove barriers to life-saving therapies. The round was led by LRVHealth, with participation from McKesson Ventures and existing investors Novartis (dRx Capital), Onco360 (BrightSpring Health Services), Hearst Ventures, and HealthX Ventures. This investment brings RxLightning's total capital raised since inception to $20.5 million.
RxLightning digitizes, automates, and streamlines the historically manual specialty medication onboarding process. With RxLightning, providers can quickly and easily complete patient enrollment for every specialty medication in every therapeutic area, helping reduce paperwork, streamline communication, and accelerate speed-to-therapy. Through the company's MedAccess Ecosystem, patients, providers, specialty pharmacies, and pharmaceutical manufacturers have insights into each step of the patient onboarding journey.
(c) by Massinvestor, Inc. For contact info, please check out our about